Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Progressive Loss of Brain Volume in Children with Sickle Cell Anemia: A Report from the Silent Cerebral Infarct Transfusion Trial Cohort
source: American Society of Hematology
year: 2015
authors: Odianosen Eigbire-Molen, Deepika S. Darbari, Maria R. Ponisio, Mikhail V. Milchenko, Mark J. Rodeghier, James F. Casella, Robert McKinstry, Michael R. DeBaun
summary/abstract:Introduction: Neurological injury is a common complication of sickle cell anemia (SCA). SCA is the most common cause of stroke in children between 1-14 years of age, while silent cerebral infarct is the most common neurologic injury in this population. Young children are particularly vulnerable to the adverse impact of strokes, and are at risk of cognitive and developmental deficits; thus, we sought to examine brain volume changes in children with SCA.
The Silent Cerebral Infarct Transfusion (SIT) Trial was a multicenter trial designed to determine the efficacy of blood transfusion therapy for prevention of recurrent silent cerebral infarcts in participants with SCA. This intervention trial followed 196 children with SCA aged 5-14 years randomized to receive blood transfusion therapy or observation for 36 months (DeBaun et al. N Engl J Med. 2014; 371(8):699-710). As a planned secondary analysis, we used the SIT Trial brain imaging archive to determine longitudinal brain volume change in children with SCA. We performed a multivariable analysis using demographic and clinical variables to identify predictors of brain volume change.
organization: Georgetown University School of Medicine, Washington, DC; Children's National Medical Center, Washington, DC; Washington University in St. Louis, School of Medicine; Rodeghier Consultants, Chicago; Johns Hopkins University School of Medicine, Baltimore; Vanderbilt University School of Medicine, Nashvilleread more
+myBinderRelated Content
-
Coagulation profile of sickle cell patients with leg ulcersLeg ulcers are a serious complication of...
-
Chronic Opioid Therapy and Central Sensitization in Sickle Cell DiseaseChronic opioid therapy (COT) for chronic...
-
Researchers ID key drivers of heart complications in sickle cell anemiaStudy opens path to earlier diagnosis, t...
-
First systemic evidence for safety of tPA in stroke patients with sickle cell diseaseIn the largest report on acute stroke in...
-
Shakir Cannon, advocate for minority health, diesShakir Lateef Cannon, a 34-year-old advo...
-
SCD Patients Benefit From Early Rivipansel Treatment for VOCs, New Analyses ShowStarting treatment with rivipansel (GMI-...
-
Randomized Trials Needed to Assess Benefits of Salmonella Vaccines in SCD Patients, Study SaysRandomized controlled trials are needed ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.